Table 2.
The methodological quality of the included trials.
| First author year | A | B | C | D | E | F | G | H | I | J | K | L |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhang 2010 [12] | ? | ? | − | − | ? | − | − | ? | + | + | + | + |
| Wu 2011 [23] | ? | ? | − | − | ? | − | − | ? | + | + | + | + |
| Zhang 2004 [24] | ? | ? | − | − | ? | − | − | ? | + | + | + | + |
| Guo 2009 [25] | ? | ? | − | − | ? | − | − | ? | + | + | + | + |
| Jia 2010 [26] | ? | ? | − | − | ? | − | − | ? | + | + | + | + |
| Fang 2005 [27] | ? | ? | − | − | ? | − | − | ? | + | + | + | + |
| Zhang 2012 [28] | ? | ? | − | − | ? | − | − | ? | + | + | + | + |
| Li 2011 [29] | ? | ? | − | − | ? | − | − | ? | + | + | + | + |
| Kang 2006 [30] | ? | ? | − | − | ? | − | − | ? | + | + | + | + |
| Lin 2008 [31] | ? | ? | − | − | ? | − | − | ? | + | + | + | + |
| Chen 2007 [32] | ? | ? | − | − | ? | − | − | ? | + | + | + | + |
| Yan 2004 [33] | ? | ? | − | − | ? | − | − | ? | + | + | + | + |
| Cui 2005 [34] | ? | ? | − | − | ? | − | − | ? | + | + | + | + |
| Liu 2010 [35] | ? | ? | − | − | ? | − | − | ? | + | + | + | + |
| Shi 1995 [36] | ? | ? | − | − | ? | − | − | ? | + | + | + | + |
| Run 2001 [37] | ? | ? | − | − | ? | − | − | ? | + | + | + | + |
| Wang 2005 [38] | ? | ? | − | − | ? | − | − | ? | + | + | + | + |
| Lv 2009 [39] | ? | ? | ? | ? | ? | − | − | ? | + | + | + | + |
| Zheng 2004 [40] | ? | ? | − | − | ? | − | − | ? | + | + | + | + |
A: adequate sequence generation; B: concealment of allocation; C: blinding (patient); D: blinding (investigator); E: blinding (assessor); F: incomplete outcome data addressed (ITT analysis); G: incomplete outcome data addressed (dropouts); H: free of selective reporting; I: similarity at baseline; J: cointerventions constant; K: compliance acceptable; L: timing outcome assessments. +Yes, −No, ?Unclear.